Guidance for the evaluation and treatment of hereditary and acquired thrombophilia.

Utility of thrombophilia testing in patients with venous thrombo-embolism. J Thorac Dis (2016) 0.75

Thrombophilia with an onset symptom of intracranial venous thrombosis: A case report and review of the literature. Exp Ther Med (2017) 0.75

Recurrent pregnancy loss: current perspectives. Int J Womens Health (2017) 0.75

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood (1996) 6.05

Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med (2005) 5.94

VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.50

Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet (2014) 4.18

INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA. Thromb Diath Haemorrh (1965) 3.80

Deficiency of protein C in congenital thrombotic disease. J Clin Invest (1981) 3.56

The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol (2008) 3.50

Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ (2011) 3.28

Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol (2006) 3.08

Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA (2005) 3.04

Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet (2003) 2.81

D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63

Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol (2005) 2.10

Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation (2010) 2.05

Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med (1984) 1.98

Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood (2009) 1.93

The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb Haemost (2009) 1.83

Clinical guidelines for testing for heritable thrombophilia. Br J Haematol (2010) 1.79

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ (2008) 1.78

Evidence-based indications for thrombophilia screening. Vasa (2008) 1.74

Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71

American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med (2001) 1.70

A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost (2010) 1.53

Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci U S A (1994) 1.51

Familial risk of venous thromboembolism in first-, second- and third-degree relatives: a nationwide family study in Sweden. Thromb Haemost (2013) 1.50

Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA (2009) 1.46

Recommendations for the prevention of pregnancy-associated venous thromboembolism. Aust N Z J Obstet Gynaecol (2011) 1.46

Factors that predict thrombosis in relatives of patients with venous thromboembolism. Blood (2014) 1.45

Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess (2006) 1.27

Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med (2011) 1.16

Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost (2012) 1.11

Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol (2013) 1.09

Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood (2014) 1.06

Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev (2014) 1.05

The value of family history as a risk indicator for venous thrombosis. Arch Intern Med (2009) 1.04

Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol (2007) 1.04

Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost (2005) 1.01

Should patients with venous thromboembolism be screened for thrombophilia? Am J Med (2008) 1.00

Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. Thromb Res (2015) 0.99

Post-thrombotic syndrome: a clinical review. J Thromb Haemost (2013) 0.97

Evidence-based approach to thrombophilia testing. J Thromb Thrombolysis (2011) 0.93

The psychological impact of testing for thrombophilia: a systematic review. J Thromb Haemost (2008) 0.92

Thrombophilia: 2009 update. Curr Treat Options Cardiovasc Med (2009) 0.92

Familial risk of venous thromboembolism: a nationwide cohort study. J Thromb Haemost (2011) 0.90

Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost (2005) 0.90

Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril (1999) 0.89

Practice bulletin no. 124: inherited thrombophilias in pregnancy. Obstet Gynecol (2011) 0.87

The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med (2002) 0.87

ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. Obstet Gynecol (2013) 0.86

Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc (2009) 0.86

The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost (1999) 0.86

Risk of obstetric and thromboembolic complications in family members of women with previous adverse obstetric outcomes carrying common inherited thombophilias. J Thromb Haemost (2012) 0.85

Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol (2009) 0.84

Longer legs are associated with greater risk of incident venous thromboembolism independent of total body height. The Longitudinal Study of Thromboembolism Etiology (LITE). Thromb Haemost (2011) 0.84

Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study. Blood (2013) 0.84

Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res (2009) 0.83

Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin Thromb Hemost (2005) 0.82

Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thromb Res (2004) 0.82

Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost (2008) 0.81

Knowledge and educational needs of individuals with the factor V Leiden mutation. J Thromb Haemost (2003) 0.81

Testing for thrombophilia: an evidence-based approach. Postgrad Med J (2006) 0.81

Is ABO blood group truly a risk factor for thrombosis and adverse outcomes? World J Cardiol (2014) 0.81

Thrombophilia testing in women with venous thrombosis: the 4 P's approach. Clin Chem (2013) 0.79

Association between thrombophilia and the post-thrombotic syndrome: a systematic review and meta-analysis. J Thromb Haemost (2014) 0.79

The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism. Thromb Haemost (2012) 0.79

Delineating the Hemostaseome as an aid to individualize the analysis of the hereditary basis of thrombotic and bleeding disorders. Hum Genet (2011) 0.78

Who should be tested for thrombophilia? Genet Med (2011) 0.78

Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. Thromb Haemost (2013) 0.78

Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseilles-NImes prediction model. J Thromb Haemost (2014) 0.78

Thromboprophylaxis in pregnancy: who and how? Obstet Gynecol Clin North Am (2010) 0.77

Thrombophilia. Clin Appl Thromb Hemost (2013) 0.77

Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis (2015) 0.77

Thrombophilia screening--at the right time, for the right patient, with a good reason. Clin Chem Lab Med (2010) 0.76

B blood group: A strong risk factor for venous thromboembolism recurrence. Thromb Res (2015) 0.76

The ASH Choosing Wisely®campaign: five hematologic tests and treatments to question. Hematology Am Soc Hematol Educ Program (2013) 0.76

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.29

Prevention of thrombosis in antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program (2016) 0.75

Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. Lancet Haematol (2020) 0.75

What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies? Hematology Am Soc Hematol Educ Program (2016) 0.75